Overview

A Clinical Trial of Patients With Melanoma

Status:
Withdrawn

Trial end date:
2017-07-17

Target enrollment:

Participant gender:

Summary

This study is being done to find out if the combination of dabrafenib, trametinib and digoxin will lessen the side effects that you may experience and to measure your response and duration of response to the combination of drugs.

Phase:

Phase 1

Details

Lead Sponsor:

University of Texas Southwestern Medical Center

Treatments:

Dabrafenib
Digoxin
Trametinib